Brief: Day One Announces FDA Acceptance Of NDA And Priority Review For Tovorafenib

Day One Biopharmaceuticals

30/10/2023 12:06

Oct 30 (Reuters) - Day One Biopharmaceuticals Inc
 DAWN.O :
    * DAY ONE ANNOUNCES FDA ACCEPTANCE OF NDA AND PRIORITY
REVIEW FOR
TOVORAFENIB IN RELAPSED OR PROGRESSIVE PEDIATRIC LOW-GRADE
GLIOMA (PLGG)
    * DAY ONE BIOPHARMACEUTICALS INC - FDA IS NOT CURRENTLY
PLANNING
TO HOLD AN ADVISORY COMMITTEE MEETING TO DISCUSS APPLICATION
    * DAY ONE BIOPHARMACEUTICALS INC -  PDUFA DATE OF APRIL 30,
2024
    * DAY ONE BIOPHARMACEUTICALS - FDA GRANTED PRIORITY REVIEW
AND
ASSIGNED A PRESCRIPTION DRUG USER FEE ACT TARGET ACTION DATE OF
APRIL 30, 2024

Source text for Eikon:  ID:nGNX7x1ByG 
Further company coverage:  DAWN.O 

 ((Reuters.Briefs@thomsonreuters.com;))